Related Experiment Video
Updated: Aug 19, 2026
Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
Published on: April 8, 2016
Magmas expression in neoplastic human prostate
Paul T Jubinsky1, Mary K Short, George Mutema
1Division of Pediatric Hematology/Oncology, Albert Einstein College of Medicine, Bronx, NY, USA. pjubinsk@aecom.yu.edu
Abstract:
Magmas, is a 13-kDa mitochondrial protein which is ubiquitously expressed in eukaryotic cells. It was identified as a granulocyte-macrophage-colony stimulating factor (GM-CSF) inducible gene in hematopoietic cells and has a key role in the transport of mitochondrial proteins in yeast. Because GM-CSF receptor levels are elevated in prostate cancer, Magmas expression was examined in normal and neoplastic tissue. Magmas protein levels were barely detectable in non-neoplastic prostate glands. Increased amounts were observed in some samples of intraepithelial neoplasia. Approximately one half of the adenocarcinoma samples examined had weak Magmas expression, while the remainder had intermediate to high levels. The increased Magmas observed in malignant tissue was a result of higher protein expression and not from changes in mitochondrial content. Interestingly, in some patients, the normal prostate tissue had more Magmas message than the malignant portion. The results indicated that Magmas expression in prostate cancer is heterogeneous and independent of clinical stage and Gleason score. Further studies are needed to determine if Magmas expression has prognostic significance in prostate cancer.
Insights
Magmas protein is often elevated in prostate cancer, but its expression varies greatly. Further research is needed to determine if Magmas levels can predict prostate cancer outcomes.
Area of Science:
- Mitochondrial biology
- Cancer research
- Prostate cancer diagnostics
Background:
- Magmas is a mitochondrial protein involved in protein transport.
- Elevated granulocyte-macrophage-colony stimulating factor (GM-CSF) receptor levels are noted in prostate cancer.
- Understanding Magmas expression in prostate cancer is crucial given its role in cellular processes.
Purpose of the Study:
- To investigate Magmas protein and messenger RNA expression in normal and neoplastic prostate tissues.
- To correlate Magmas expression levels with prostate cancer characteristics such as clinical stage and Gleason score.
Main Methods:
- Western blot analysis was used to quantify Magmas protein levels.
- Immunohistochemistry was employed to assess Magmas protein distribution in tissue samples.
- Quantitative real-time PCR was utilized to measure Magmas messenger RNA levels.
Main Results:
- Magmas protein was barely detectable in normal prostate glands but increased in intraepithelial neoplasia and adenocarcinoma.
- Approximately 50% of prostate adenocarcinomas showed weak Magmas expression, while the rest exhibited intermediate to high levels.
- Increased Magmas in malignant tissue resulted from higher protein expression, not altered mitochondrial content.
- In some cases, normal prostate tissue showed higher Magmas messenger RNA than malignant portions, indicating heterogeneous expression.
Conclusions:
- Magmas expression in prostate cancer is heterogeneous and not directly correlated with clinical stage or Gleason score.
- The observed variability suggests Magmas may not be a straightforward biomarker for prostate cancer progression.
- Further investigation is warranted to explore the potential prognostic significance of Magmas expression in prostate cancer.
